These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 30555458)

  • 1. HLA-DR in Cytotoxic T Lymphocytes Predicts Breast Cancer Patients' Response to Neoadjuvant Chemotherapy.
    Saraiva DP; Jacinto A; Borralho P; Braga S; Cabral MG
    Front Immunol; 2018; 9():2605. PubMed ID: 30555458
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of HLA-DR in Cytotoxic T Lymphocytes: A Validated Predictive Biomarker and a Potential Therapeutic Strategy in Breast Cancer.
    Saraiva DP; Azeredo-Lopes S; Antunes A; Salvador R; Borralho P; Assis B; Pereira IL; Seabra Z; Negreiros I; Jacinto A; Braga S; Cabral MG
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359741
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effector Mechanisms of CD8+ HLA-DR+ T Cells in Breast Cancer Patients Who Respond to Neoadjuvant Chemotherapy.
    Osuna-Gómez R; Arqueros C; Galano C; Mulet M; Zamora C; Barnadas A; Vidal S
    Cancers (Basel); 2021 Dec; 13(24):. PubMed ID: 34944786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative Analysis of Immune Infiltrates in Primary Melanoma.
    Gartrell RD; Marks DK; Hart TD; Li G; Davari DR; Wu A; Blake Z; Lu Y; Askin KN; Monod A; Esancy CL; Stack EC; Jia DT; Armenta PM; Fu Y; Izaki D; Taback B; Rabadan R; Kaufman HL; Drake CG; Horst BA; Saenger YM
    Cancer Immunol Res; 2018 Apr; 6(4):481-493. PubMed ID: 29467127
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of HLA-DR expression and T-lymphocyte infiltration in osteosarcoma.
    Trieb K; Lechleitner T; Lang S; Windhager R; Kotz R; Dirnhofer S
    Pathol Res Pract; 1998; 194(10):679-84. PubMed ID: 9820863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Strong CD8+ lymphocyte infiltration in combination with expression of HLA class I is associated with better tumor control in breast cancer patients treated with neoadjuvant chemotherapy.
    de Groot AF; Blok EJ; Charehbili A; Engels CC; Smit VTHBM; Dekker-Ensink NG; Putter H; Meershoek-Klein Kranenbarg E; van de Velde CJH; Liefers GJ; Nortier JWR; Kuppen PJK; van der Burg SH; Kroep JR
    Breast Cancer Res Treat; 2019 Jun; 175(3):605-615. PubMed ID: 30868392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast Cancer Patients: Who Would Benefit from Neoadjuvant Chemotherapies?
    Yao L; Jia G; Lu L; Ma W
    Curr Oncol; 2022 Jul; 29(7):4902-4913. PubMed ID: 35877249
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Requirements for lysis of activated T cells by class-II-restricted cytolytic T-lymphocytes.
    Eljaafari A; Dorval I; Zeliszewski D; Le Gac S; Sterkers G
    Hum Immunol; 1992 Sep; 35(1):50-9. PubMed ID: 1362200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses.
    Karkada M; Weir GM; Quinton T; Sammatur L; MacDonald LD; Grant A; Liwski R; Juskevicius R; Sinnathamby G; Philip R; Mansour M
    J Immunother; 2010 Apr; 33(3):250-61. PubMed ID: 20445345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peripheral leukocytes with HLA-DR+/CD8- phenotype are associated with prognosis in patients with lung cancer.
    Nakamura H; Saji H; Aute I; Kawasaki N; Hosaka M; Ogata A; Saijo T; Kato H
    Anticancer Res; 2003; 23(5b):4149-52. PubMed ID: 14666616
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Melanoma specific Th1 cytotoxic T lymphocyte lines in Vogt-Koyanagi-Harada disease.
    Norose K; Yano A
    Br J Ophthalmol; 1996 Nov; 80(11):1002-8. PubMed ID: 8976730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The composition of T cell infiltrates varies in primary invasive breast cancer of different molecular subtypes as well as according to tumor size and nodal status.
    Glajcar A; Szpor J; Hodorowicz-Zaniewska D; Tyrak KE; Okoń K
    Virchows Arch; 2019 Jul; 475(1):13-23. PubMed ID: 31016433
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adoptive immunotherapy combined with FP treatment for head and neck cancer: An in vitro study.
    Nishio-Nagai M; Suzuki S; Yoshikawa K; Ueda R; Kazaoka Y
    Int J Oncol; 2017 Nov; 51(5):1471-1481. PubMed ID: 29048671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The novel C24D synthetic polypeptide inhibits binding of placenta immunosuppressive ferritin to human T cells and elicits anti-breast cancer immunity in vitro and in vivo.
    Solodeev I; Zahalka MA; Moroz C
    Neoplasia; 2014 Sep; 16(9):741-50. PubMed ID: 25246274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A CD80-transfected human breast cancer cell variant induces HER-2/neu-specific T cells in HLA-A*02-matched situations in vitro as well as in vivo.
    Gückel B; Stumm S; Rentzsch C; Marmé A; Mannhardt G; Wallwiener D
    Cancer Immunol Immunother; 2005 Feb; 54(2):129-40. PubMed ID: 15365776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes.
    Lu C; Klement JD; Ibrahim ML; Xiao W; Redd PS; Nayak-Kapoor A; Zhou G; Liu K
    J Immunother Cancer; 2019 Jun; 7(1):157. PubMed ID: 31228946
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Functional Change of Effector Tumor-Infiltrating CCR5
    Chen PY; Wu CY; Fang JH; Chen HC; Feng LY; Huang CY; Wei KC; Fang JY; Lin CY
    Front Immunol; 2019; 10():2395. PubMed ID: 31649684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dissimilar patterns of tumor-infiltrating immune cells at the invasive tumor front and tumor center are associated with response to neoadjuvant chemotherapy in primary breast cancer.
    König L; Mairinger FD; Hoffmann O; Bittner AK; Schmid KW; Kimmig R; Kasimir-Bauer S; Bankfalvi A
    BMC Cancer; 2019 Feb; 19(1):120. PubMed ID: 30717704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-associated macrophages in human breast cancer parenchyma negatively correlate with lymphatic metastasis after neoadjuvant chemotherapy.
    Mitrofanova I; Zavyalova M; Telegina N; Buldakov M; Riabov V; Cherdyntseva N; Kzhyshkowska J
    Immunobiology; 2017 Jan; 222(1):101-109. PubMed ID: 27510849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Expression of SART3 antigen and induction of CTLs by SART3-derived peptides in breast cancer patients.
    Suefuji Y; Sasatomi T; Shichijo S; Nakagawa S; Deguchi H; Koga T; Kameyama T; Itoh K
    Br J Cancer; 2001 Apr; 84(7):915-9. PubMed ID: 11286471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.